Cargando…

Tadalafil in the treatment of erectile dysfunction

The treatment for erectile dysfunction (ED) was revolutionized with the development of phosphodiesterase type 5 (PDE5) inhibitors. Tadalafil (Cialis(®); Eli Lilly and Company, Indianapolis, IN, USA) is the newest and most versatile PDE5 inhibitor in the clinical armamentarium for the treatment of ED...

Descripción completa

Detalles Bibliográficos
Autores principales: Coward, Robert M, Carson, Culley C
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2643112/
https://www.ncbi.nlm.nih.gov/pubmed/19337438
_version_ 1782164687107915776
author Coward, Robert M
Carson, Culley C
author_facet Coward, Robert M
Carson, Culley C
author_sort Coward, Robert M
collection PubMed
description The treatment for erectile dysfunction (ED) was revolutionized with the development of phosphodiesterase type 5 (PDE5) inhibitors. Tadalafil (Cialis(®); Eli Lilly and Company, Indianapolis, IN, USA) is the newest and most versatile PDE5 inhibitor in the clinical armamentarium for the treatment of ED. Its most unique characteristic is its long half-life of 17.5 hours, which lends itself to a longer therapeutic window with on-demand dosing and effective steady-state plasma concentrations with once-daily dosing. Clinical trials have proven its safety and efficacy with both dosing strategies for all severities and etiologies of ED, including difficult-to-treat ED. This thorough review will discuss ED, the physiology of penile erection and the role of PDE5, and all aspects of tadalafil, from its development, through its pharmacology, to its latest clinical studies and indications.
format Text
id pubmed-2643112
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-26431122009-04-01 Tadalafil in the treatment of erectile dysfunction Coward, Robert M Carson, Culley C Ther Clin Risk Manag Review The treatment for erectile dysfunction (ED) was revolutionized with the development of phosphodiesterase type 5 (PDE5) inhibitors. Tadalafil (Cialis(®); Eli Lilly and Company, Indianapolis, IN, USA) is the newest and most versatile PDE5 inhibitor in the clinical armamentarium for the treatment of ED. Its most unique characteristic is its long half-life of 17.5 hours, which lends itself to a longer therapeutic window with on-demand dosing and effective steady-state plasma concentrations with once-daily dosing. Clinical trials have proven its safety and efficacy with both dosing strategies for all severities and etiologies of ED, including difficult-to-treat ED. This thorough review will discuss ED, the physiology of penile erection and the role of PDE5, and all aspects of tadalafil, from its development, through its pharmacology, to its latest clinical studies and indications. Dove Medical Press 2008-12 2008-12 /pmc/articles/PMC2643112/ /pubmed/19337438 Text en © 2008 Dove Medical Press Limited. All rights reserved
spellingShingle Review
Coward, Robert M
Carson, Culley C
Tadalafil in the treatment of erectile dysfunction
title Tadalafil in the treatment of erectile dysfunction
title_full Tadalafil in the treatment of erectile dysfunction
title_fullStr Tadalafil in the treatment of erectile dysfunction
title_full_unstemmed Tadalafil in the treatment of erectile dysfunction
title_short Tadalafil in the treatment of erectile dysfunction
title_sort tadalafil in the treatment of erectile dysfunction
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2643112/
https://www.ncbi.nlm.nih.gov/pubmed/19337438
work_keys_str_mv AT cowardrobertm tadalafilinthetreatmentoferectiledysfunction
AT carsonculleyc tadalafilinthetreatmentoferectiledysfunction